| GTO ID | GTC2703 |
| Trial ID | NCT04911166 |
| Disease | Non-Small Cell Lung Cancer |
| Altered gene | IL-12 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | Adv-IL12 |
| Co-treatment | Atezolizumab |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy |
| Year | 2021 |
| Country | United States |
| Company sponsor | The Methodist Hospital Research Institute |
| Other ID(s) | PRO00026826 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||||
|
|||||||||